Inhaled Anesthetic Pharmacokinetics

Understanding how inhaled anesthetics travel from the anesthetic machine into a patient's brain is fundamental to safe clinical practice. This process, known as pharmacokinetics, dictates the speed of induction, the depth of anesthesia, and the rate of recovery. Mastering two core concepts—minimum alveolar concentration and blood-gas solubility—provides the framework for predicting anesthetic behavior and making informed agent selections for different patients and procedures.

The Foundation: Potency and Solubility

The clinical effects of volatile anesthetics are defined by two primary properties: their potency and their solubility in blood. Potency tells you how much you need, while solubility tells you how fast it will work.

Minimum Alveolar Concentration (MAC) is the standard measure of anesthetic potency. It is defined as the alveolar concentration of an anesthetic, at one atmosphere, that prevents movement in 50% of patients in response to a standardized surgical incision. Think of MAC as the "dose" required to achieve a specific effect; a low MAC indicates a very potent drug (you need less of it), while a high MAC indicates a less potent drug (you need more). For example, desflurane has a MAC of approximately 6%, meaning you need a 6% concentration in the alveoli, whereas sevoflurane has a MAC of about 2%, making it roughly three times more potent.

The speed at which an anesthetic achieves its desired effect in the brain is governed by its blood-gas partition coefficient (${\lambda }_{blood/gas}$). This number represents the solubility of the anesthetic in blood relative to gas at equilibrium. It answers the question: "How readily does the anesthetic leave the alveolar gas and dissolve into the blood?" A low blood-gas partition coefficient (e.g., 0.45 for desflurane) means the anesthetic has low solubility in blood. It does not "linger" in the blood; instead, it rapidly equilibrates and moves on to the brain, leading to a fast induction and fast recovery. Conversely, a high coefficient (e.g., 10 for halothane) indicates high solubility, meaning the blood acts like a large reservoir, soaking up the anesthetic and slowing the rise in alveolar and brain partial pressure, resulting in slower induction and emergence.

Clinical Application: Agent Selection and Onset Speed

The principles of solubility and potency directly translate to why certain agents are chosen for specific phases of anesthesia. Nitrous oxide has an extremely low blood-gas partition coefficient (0.47) and is therefore relatively insoluble. This low solubility is the primary reason for its rapid onset of action. When you turn on nitrous oxide, its alveolar concentration rises quickly, speeding the patient toward unconsciousness.

For modern inhalation induction—particularly in pediatric patients or adults with a difficult airway—sevoflurane is the preferred induction agent. Its combination of a relatively low blood-gas partition coefficient (0.65) and non-pungent odor allows for a smooth and rapid transition to unconsciousness without causing airway irritation. In contrast, desflurane has the lowest solubility of all modern volatile agents (${\lambda }_{blood/gas}$ = 0.45), which should theoretically make it the fastest. However, its extreme pungency irritates the airways, often causing coughing, breath-holding, and laryngospasm if used for a mask induction. Therefore, desflurane is almost exclusively used for maintenance of anesthesia after the airway is secured, where its low solubility contributes to very rapid recovery.

Concentration and Second Gas Effects

Two unique pharmacokinetic phenomena occur when using high concentrations of inhaled agents, particularly nitrous oxide. The concentration effect states that the higher the inspired concentration of an anesthetic, the faster its alveolar concentration will rise toward the inspired level. This is because a high inflow of fresh gas rapidly replaces the anesthetic taken up by the blood, minimizing the dilutional effect.

The second gas effect is a consequence of the concentration effect. When a high volume of a "first gas" like nitrous oxide is taken up rapidly from the alveoli, it creates a sub-atmospheric pressure that literally pulls more of a concurrently administered "second gas" (like oxygen or sevoflurane) into the alveoli. This increases the alveolar concentration and speeds the uptake of the second gas. In practice, using 70% nitrous oxide not only provides its own rapid effects but also accelerates the induction from a co-administered volatile agent like sevoflurane.

Factors That Modify Anesthetic Requirements (MAC)

MAC is a useful benchmark, but it is not a fixed number for every patient. A variety of physiological, pharmacological, and pathological factors can increase or decrease a patient's actual MAC requirement.

• Age: MAC is highest in infants, peaks around 6 months of age, and then progressively decreases with advancing age. An 80-year-old patient typically requires about 25% less volatile anesthetic than a 20-year-old for the same surgical stimulus.
• Temperature: Hypothermia linearly decreases MAC. For every 1°C decrease in core body temperature, MAC decreases by approximately 5-7%. Conversely, hyperthermia can increase MAC, though this is complicated by febrile illness.
• Concurrent Medications: The addition of other central nervous system depressants significantly reduces MAC. Premedications like benzodiazepines (midazolam) or opioids (fentanyl, morphine) have a profound MAC-sparing effect. This is why a balanced anesthetic technique, using lower doses of multiple drugs, is common practice.
• Other Factors: Chronic alcohol or stimulant abuse can increase MAC, while acute intoxication decreases it. Pregnancy decreases MAC by up to 30%, and severe anemia or hypoxia also reduces requirements.

Common Pitfalls

1. Equating Low Solubility with Ideal Induction: Assuming the agent with the lowest blood-gas coefficient (desflurane) is always the best for rapid induction ignores its pungency. The clinical reality of airway irritation makes the slightly more soluble but non-irritating sevoflurane the superior choice for inhalation induction.
2. Ignoring Context When Applying MAC: Using a textbook MAC value without adjusting for patient-specific factors like age, temperature, and concurrent opioid use can lead to under- or over-dosing. MAC is a starting point for dosing, not an absolute endpoint.
3. Overlooking the Second Gas Effect in Emergence: While the second gas effect speeds induction, it has a reverse implication during emergence. When nitrous oxide is turned off at the end of a case, its rapid diffusion out of the blood and into the alveoli can dilute alveolar oxygen (a phenomenon called diffusion hypoxia). Failing to administer supplemental oxygen during this period is a dangerous oversight.
4. Confusing Potency with Speed: A potent drug (low MAC) is not necessarily a fast drug. Halothane is very potent (low MAC) but has high solubility, making it slow. Desflurane is less potent (high MAC) but has very low solubility, making it fast. Potency (MAC) and speed (solubility) are independent properties.

Summary

• Minimum Alveolar Concentration (MAC) is the core measure of potency, defining the alveolar concentration needed to prevent movement in 50% of patients.
• The blood-gas partition coefficient determines speed, with low solubility (low coefficient) leading to fast induction and recovery, as seen with nitrous oxide and desflurane.
• In clinical practice, sevoflurane is preferred for inhalation induction due to its favorable balance of moderate solubility and non-pungent properties, while desflurane is reserved for maintenance.
• The second gas effect and concentration effect are pharmacokinetic phenomena that accelerate induction when using high concentrations of nitrous oxide alongside another volatile agent.
• MAC is significantly modified by age (decreases with age), hypothermia (decreases MAC), and concurrent medications like opioids and benzodiazepines (profoundly decrease MAC).